Evidence map›Paper›PMID 25232245›Full record

ReviewWorld journal of gastroenterology2014

Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.

Kareem Hassan, Varun Bhalla, Mohammed Ezz El Regal, H Hesham A-Kader

2 registry-linked trialsAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 82 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03135873 nacompletednot on this mapstarted 2017, after this paper: background citation

Mastiha Treatment for Obese With NAFLD Diagnosis

TypeinterventionalSponsorHarokopio UniversityRan2017 to 2019Enrolled100ConditionsNon Alcoholic Fatty Liver DiseaseArmsMastiha, Placebo
NCT05200156 naunknown statusnot on this mapstarted 2022, after this paper: background citation

The Impact Of Choline Administration On Oxidative Stress And Clinical Outcome Of Patients With Non-Alcoholic Fatty Liver Disease NAFLD

TypeinterventionalSponsorAin Shams UniversityRan2022 to 2024Enrolled100ConditionsNon-Alcoholic Fatty Liver DiseaseArmsPhosphatidyl Choline
3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. An association study ofBiochemistry and biophysics reports · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. A decade of liver organoids: Advances in disease modeling.Clinical and molecular hepatology · 2023
    Review
  16. Article
  17. Review
  18. Protective effects and mechanisms of Lizhong decoction against non-alcoholic fatty liver disease in a rat model.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022
    Article
  19. Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kareem HassanKareem Hassan, Varun Bhalla, Mohammed Ezz El Regal, H Hesham A-Kader, Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, The University of Arizona, Tucson, AZ 85724, United States.
Varun BhallaKareem Hassan, Varun Bhalla, Mohammed Ezz El Regal, H Hesham A-Kader, Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, The University of Arizona, Tucson, AZ 85724, United States.
Mohammed Ezz El RegalKareem Hassan, Varun Bhalla, Mohammed Ezz El Regal, H Hesham A-Kader, Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, The University of Arizona, Tucson, AZ 85724, United States.
H Hesham A-KaderKareem Hassan, Varun Bhalla, Mohammed Ezz El Regal, H Hesham A-Kader, Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, The University of Arizona, Tucson, AZ 85724, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nonalcoholic fatty liver disease (NAFLD) is quickly becoming one of the most prominent causes of liver disease worldwide. The increasing incidence of NAFLD is tied to the obesity epidemic and the subsequent metabolic derangements brought along with it. Current efforts to elucidate the mechanism and causes of the disease have answered some questions, but much remains unknown about NAFLD. The aim of this article is to discuss the current knowledge regarding the pathogenesis of the disease, as well as the current and future diagnostic, preventative, and therapeutic options available to clinicians for the management of NAFLD.

Indexed as

EpidemicsAnimalsDisease ProgressionHumansIncidenceLiverMetabolic DiseasesNon-alcoholic Fatty Liver DiseaseObesityPrognosisRisk FactorsTime FactorsDiagnosisImagingManagementMetforminNonalcoholic fatty liver diseaseNonalcoholic steatohepatitisPathogenesisPrevalenceSteatohepatitisThiazolidinedioneTreatmentsVitamin E

Identifiers

PMID25232245
PMCPMC4161796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.